Pediatric ESAP 2025 - 2026
Image For Activity Cover
Availability
On-Demand
2 Courses
Expires on Dec 31, 2027
Cost
Member: $260.00
Non-Member: $365.00
In-Training Member: $209.00
Resident Member: $209.00
Resident Non-Member: $365.00
Credit Offered
40 AMA PRA Category 1 Credits
40 ABP-MOC Points
40 Participation Credits
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

The Pediatric Endocrine Self-Assessment Program is a self-study curriculum aimed at physicians seeking initial certification or recertification in endocrinology, program directors interested in a testing and training instrument, and clinicians simply wanting a self-assessment and a broad review of endocrinology. Pediatric ESAP 2025-2026 consists of 100 brand-new multiple-choice questions in all areas of endocrinology, diabetes, and metabolism. There is extensive discussion of each correct answer and references. For accessibility for international practitioners, SI units are included.

Pediatric ESAP is updated with brand-new questions every other year. 

Learning Options
Assess your clinical knowledge through different learning modes:

  • Learning Mode: This is the "traditional" Pediatric ESAP. Answer 100 questions and receive immediate feedback and view the detail answer rationale. This mode must be completed with a passing score of 70% in order to earn CME and MOC.
  • Mock Exam Mode: Perfect for simulating an exam. Retake this mock exam as often as you like and each time the questions will be re-organized. Feedback will be provided after completion of the exam.
    • Topical Learning Mode: Within Mock Exam Mode, you have the option to create your own exams by choosing the topic(s) to be included

METHOD OF PARTICIPATION
This enduring material is presented online and in print format. The estimated time to complete this activity, including review of material, is 40 hours. Participants must achieve a minimum score of 70% to claim CME credit and MOC points. After initially completing the module(s), if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Participants also have the option to clear all answers and start over. Credit is only available on the standard Pediatric ESAP learning mode.

LAST REVIEW DATE: January 2025

ACTIVITY RELEASE DATE: March 2025

ACTIVITY EXPIRATION DATE: December 31, 2027 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits and ABP Medical Knowledge MOC points)

Pediatric ESAP 2025-2026 is a self-study curriculum aimed at physicians seeking initial certification or recertification in pediatric endocrinology, program directors interested in a testing and training instrument, and clinicians simply wanting a self-assessment and a broad review of pediatric endocrinology.

Upon completion of this educational activity, participants will be able to:

  • Recognize clinical manifestations of pediatric endocrine, growth, and metabolic disorders and select among current options for diagnosis, management, and therapy.
  • Identify risk factors for endocrine and metabolic disorders in pediatric patients and develop strategies for prevention.
  • Evaluate pediatric endocrine and metabolic manifestations of systemic disorders.
  • Use current, evidence-based clinical guidelines and treatment recommendations to guide diagnosis and treatment of pediatric endocrine and metabolic disorders.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 40.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 40 MOC points in the American Board of Pediatric’s (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Liuska M. Pesce, MD, Co-Chair
Clinical Professor
Pediatric Thyroid Clinic Director
Stead Family Children’s Hospital
Division of Pediatric Endocrinology and Diabetes
University of Iowa Carver College of Medicine

Ryan S. Miller, MD, Co-Chair
Division Director, Pediatric Endocrinology
Sinai Hospital of Baltimore

Sasigarn A. Bowden, MD
Professor of Pediatrics
Nationwide Children’s Hospital
The Ohio State University

Li Chan, MD
Reader in Molecular Endocrinology and Metabolism
Honorary Consultant in Paediatric Endocrinology
Centre for Endocrinology
William Harvey Research Institute

 Andrew Dauber, MD, MMSc
Professor of Pediatrics
George Washington University School of Medicine and Health Sciences
Chief of Endocrinology
Children’s National Hospital

Cem S. Demirci, MD
Director, Type 1 Diabetes Program
Connecticut Children’s Medical Center

Evgenia A. Gourgari, MD
Georgetown University

Colin P. Hawkes, MB BCh BAO, MD, PhD
Associate Professor of Pediatrics
University College Cork
Perelman School of Medicine
University of Pennsylvania

Shana McCormack, MD
Assistant Professor of Pediatrics
Children’s Hospital of Philadelphia

Siobhan Pittock, MB, BAO, BCH
Pediatric Endocrinologist
Mayo Clinic

Sripriya Raman, MD
Pediatric Endocrinologist
K S Pediatrics

Kyriakie Sarafoglou, MD
Professor
Department of Pediatrics-Divisions of Endocrinology and Genetics & Metabolism
Department of Experimental & Clinical Pharmacology
University of Minnesota
Director, Center for Congenital Adrenal Hyperplasia
MHealth Masonic Children's Hospital

Christine Trapp, MD
Pediatric Endocrinology, Connecticut Children’s Medical Center
Associate Fellowship Director, Pediatric Endocrinology
Assistant Professor of Pediatrics, University of Connecticut School of Medicine

Halley Wasserman, MD
Associate Professor
Cincinnati Children’s Hospital Medical Center

Ari Wassner, MD
Medical Director, Thyroid Center
Director, Endocrinology Fellowship Training Program
Associate Professor of Pediatrics
Boston Children’s Hospital
Harvard Medical School

Abbie L. Young, MS, CGC, ELS(D)
Medical Editor



STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Pediatric ESAP Faculty Working Group.

 

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationship(s): Sasigarn Bowden, MD, is an advisory board member of Alexion. Li Chan, MD, is an advisory board member of OMass Therapeutics and Great Ormond Street Hospital Children’s Charity Research. Andrew Dauber, MD, is an advisory board member of Ascendis, BioMarin, BridgeBio, Novo Nordisk, and Pfizer. He serves as a consultant for Novo Nordisk and Tyra Pharmaceuticals. He is also a grant recipient from BioMarin and Pfizer. Shana McCormack, MD, is an NIH grantee and grant reviewer. She is a grantee of the Doris Duke Charitable Foundation and the Friedreich Ataxia Research Alliance. She is a consultant for Rhythm Pharmaceuticals and Reata Pharmaceuticals. She is also a principal investigator for Rhythm Pharmaceuticals and Aegerion. Ryan S. Miller, MD, is an NIH grantee and a consultant for Novo Nordisk. Kyriakie Sarafoglou, MD, receives research support from the Office of Orphan Products Development of the Food and Drug Administration, National Institutes of Health, Neurocrine Biosciences, Spruce Biosciences, Crinetics Pharmaceuticals, Adrenas Therapeutics (BridgeBio), Alexion Pharmaceuticals, and BioMarin Pharmaceutical. She serves as a consultant for Novo Nordisk, Eton Pharmaceuticals, Neurocrine Biosciences, Spruce Biosciences, and Crinetics Pharmaceuticals on behalf of the University of Minnesota but does not receive personal income for these activities. Christine Trapp, MD, is an advisory panel member for Rhythm Pharmaceuticals. Ari Wassner, MD, is a topic peer reviewer for UpToDate (thyroid).

The following faculty reported no relevant financial relationships: Cem S. Demirci, MD; Evgenia Gourgari, MD; Colin Hawkes, MB BCh BAO, MD, PhD; Liuska M. Pesce, MD; Siobhan Pittock, MB, BAO, BCH; Sripriya Raman, MD; and Halley Wasserman, MD.

The medical editor for this program, Abbie L. Young, MS, CGC, ELS(D), reported no relevant financial relationships.

The Endocrine Society staff associated with the development of this program reported no relevant financial relationships.


DISCLAIMERS
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By